Gamida Cell Ltd. Announces Data Published In Transplantation And Cellular Therapy Suggest Antiviral Protection After Transplantation With Co's Omisirge
Portfolio Pulse from Happy Mohamed
Gamida Cell Ltd. (NASDAQ:GMDA) has published a sub-study of the Phase 3 clinical trial for Omisirge, its allogeneic stem cell transplant therapy. The study found that Omisirge facilitates faster immune reconstitution and a decreased rate of post-transplant viral infection compared to umbilical cord blood. Omisirge recipients demonstrated a significant advantage in median cell counts and received a higher median dose of CD34+ stem cells. The rate of infections in the first year were significantly lower with Omisirge.
July 11, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gamida Cell's Omisirge shows promising results in a Phase 3 sub-study, potentially boosting the company's reputation and stock value.
The positive results from the Phase 3 sub-study of Omisirge could increase investor confidence in Gamida Cell, potentially leading to an increase in the company's stock value in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100